Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
KYTHERA BIOPHRM
(NQ:
KYTH
)
21.00
USD
UNCHANGED
Official Closing Price
/ Updated:
8:10 PM EDT, May 21, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
20.92
Bid (Size)
20.90 (500)
Ask (Size)
21.00 (2100)
Prev. Close
21.00
Today's Range
20.46 - 21.31
52wk Range
14.07 - 31.93
Shares Outstanding
18,384,664
Dividend Yield
N/A
Top News
More News
Kythera Biophrm (KYTH) Posts Q1 Loss of 77c/Share
May 13, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8332287 for the full story.
Read More
from
StreetInsider.com News Articles
KYTHERA Biopharmaceuticals Announces First Quarter 2013 Operating Results
May 13, 2013
from
GlobeNewswire News Releases
More News
Read More
KYTHERA Biopharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
May 07, 2013
from
GlobeNewswire News Releases
KYTHERA Biopharmaceuticals to Release First Quarter 2013 Operating Results
May 02, 2013
from
GlobeNewswire News Releases
KYTHERA Biopharmaceuticals Presents Positive MRI Results from Phase IIb Study of ATX-101 in Reduction of Double Chin
April 13, 2013
category
Earnings
,
Contracts
,
Benzinga
, and 6 more.
from
Latest Articles from Benzinga.com
KYTHERA Biopharmaceuticals, Inc. Presents Positive Magnetic Resonance Imaging (MRI) Results from Phase IIb Study of ATX-101 in the Reduction of Submental Fat or “Double Chin”
April 13, 2013
from
Business Wire News Releases
KYTHERA Biopharmaceuticals Announces Positive Interim Phase IIIb Results from Open-Label Study of ATX-101
April 06, 2013
category
Management
,
Benzinga
,
KYTH
, and 3 more.
from
Latest Articles from Benzinga.com
KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Phase IIIb Study of ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC)
April 06, 2013
from
Business Wire News Releases
Kythera Biophrm (KYTH) Misses Q4 EPS by 28c
March 21, 2013
from
StreetInsider.com News Articles
KYTHERA Biopharmaceuticals Announces 2012 Operating Results
March 21, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here